Issuance of Priority Review Voucher; Rare Pediatric Disease Product, 71511 [2016-24947]
Download as PDF
jstallworth on DSK7TPTVN1PROD with NOTICES
Federal Register / Vol. 81, No. 200 / Monday, October 17, 2016 / Notices
security check procedures will be
performed. For parking and security
information, please refer to https://
www.fda.gov/AboutFDA/
WorkingatFDA/BuildingsandFacilities/
WhiteOakCampusInformation/
ucm241740.htm.
FOR FURTHER INFORMATION CONTACT:
Audrey Thomas, Office of Regulatory
Science and Innovation, Office of the
Chief Scientist, Food and Drug
Administration, 10903 New Hampshire
Ave., Bldg. 1, Rm. 4220, Silver Spring,
MD 20993–0002, 301–796–3520,
Audrey.Thomas@fda.hhs.gov.
SUPPLEMENTARY INFORMATION: The
purpose of this public workshop is to
provide an opportunity for stakeholders,
including scientists from government,
academia, and industry, patient
advocacy groups, clinicians,
pharmacists, and the general public to
discuss marketed generic drugs. Generic
drugs account for 88 percent of
prescriptions in the United States. In
light of the significant contributions of
generic drugs to public health, it is
important that tools are developed to
monitor marketed generic drugs to
ensure that they have the same safety
and effectiveness as their reference
listed drug. Specifically, this workshop
will include presentations on: (1)
Current generic drug surveillance
practices at FDA and in industry, (2)
public perception of generic drug
quality and effectiveness, (3) generic
drug substitution studies in patients,
and (4) development of methods and
tools to conduct postmarket surveillance
of generic drugs. The workshop will
include four panel sessions for
interaction and discussion among the
speakers and attendees.
Agenda: The agenda is available at
https://www.fda.gov/scienceresearch/
specialtopics/regulatoryscience/
ucm521545.htm.
Registration: There is no registration
fee to attend this public workshop. Seats
are limited and registration will be on
a first-come, first-served basis. Advance
registration is required and is online
only at https://www.fda.gov/
scienceresearch/specialtopics/
regulatoryscience/ucm521545.htm.
There will be no day-of, onsite
registration.
Streaming Webcast of the Public
Workshop: This public workshop will
also be Webcast. There is no registration
fee for access to the workshop via the
Webcast, but registration is still
required. Information regarding
registration and access to the Webcast
link is available at https://www.fda.gov/
scienceresearch/specialtopics/
regulatoryscience/ucm521545.htm. If
VerDate Sep<11>2014
14:22 Oct 14, 2016
Jkt 241001
you have never attended a Connect Pro
event before, test your connection at
https://collaboration.fda.gov/common/
help/en/support/meeting_test.htm. To
get a quick overview of the Connect Pro
program, visit https://www.adobe.com/
go/connectpro_overview. (FDA has
verified these Web site addresses, but
FDA is not responsible for any
subsequent changes to the Web sites
after this document publishes in the
Federal Register.)
Accommodations: Attendees are
responsible for their own hotel
accommodations. If you need special
accommodations while at FDA’s White
Oak Campus due to a disability, please
contact Shari Solomon at
Shari.Solomon@fda.hhs.gov at least 7
days in advance.
Dated: October 11, 2016.
Leslie Kux,
Associate Commissioner for Policy.
[FR Doc. 2016–25004 Filed 10–14–16; 8:45 am]
BILLING CODE 4164–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA–2014–N–0229]
Food and Drug Administration,
HHS.
ACTION:
Dated: October 6, 2016.
Leslie Kux,
Associate Commissioner for Policy.
[FR Doc. 2016–24947 Filed 10–14–16; 8:45 am]
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
Notice.
[Docket No. FDA–2014–D–0901]
The Food and Drug
Administration (FDA) is announcing the
issuance of a priority review voucher to
the sponsor of a rare pediatric disease
product application. The Federal Food,
Drug, and Cosmetic Act (the FD&C Act),
as amended by the Food and Drug
Administration Safety and Innovation
Act (FDASIA), authorizes FDA to award
priority review vouchers to sponsors of
rare pediatric disease product
applications that meet certain criteria.
FDA has determined that EXONDYS 51
(eteplirsen), manufactured by Sarepta
Therapeutics, meets the criteria for a
priority review voucher.
FOR FURTHER INFORMATION CONTACT:
Larry Bauer, Rare Diseases Program,
Center for Drug Evaluation and
Research, Food and Drug
Administration, 10903 New Hampshire
Ave., Silver Spring, MD 20993–0002,
301–796–4842, FAX: 301–796–9858,
email: larry.bauer@fda.hhs.gov.
SUPPLEMENTARY INFORMATION: FDA is
announcing the issuance of a priority
review voucher to the sponsor of a rare
pediatric disease product application.
SUMMARY:
PO 00000
Under section 529 of the FD&C Act (21
U.S.C. 360ff), which was added by
FDASIA, FDA will award priority
review vouchers to sponsors of rare
pediatric disease product applications
that meet certain criteria. FDA has
determined that EXONDYS 51
(eteplirsen), manufactured by Sarepta
Therapeutics, meets the criteria for a
priority review voucher. EXONDYS 51
(eteplirsen) is indicated for the
treatment of Duchenne muscular
dystrophy (DMD) in patients who have
a confirmed mutation of the DMD gene
that is amenable to exon 51 skipping.
For further information about the Rare
Pediatric Disease Priority Review
Voucher Program and for a link to the
full text of section 529 of the FD&C Act,
go to https://www.fda.gov/ForIndustry/
DevelopingProductsforRareDiseases
Conditions/RarePediatricDiseasePriority
VoucherProgram/default.htm. For
further information about EXONDYS 51
(eteplirsen) go to the ‘‘Drugs@FDA’’ Web
site at https://www.accessdata.fda.gov/
scripts/cder/drugsatfda/index.cfm.
BILLING CODE 4164–01–P
Issuance of Priority Review Voucher;
Rare Pediatric Disease Product
AGENCY:
71511
Frm 00037
Fmt 4703
Sfmt 4703
Abbreviated New Drug Application
Submissions—Prior Approval
Supplements Under Generic Drug User
Fee Amendments; Guidance for
Industry; Availability
AGENCY:
Food and Drug Administration,
HHS.
ACTION:
Notice of availability.
The Food and Drug
Administration (FDA or Agency) is
announcing the availability of a
guidance for industry entitled ‘‘ANDA
Submissions—Prior Approval
Supplements Under GDUFA.’’ The
Generic Drug User Fee Amendments of
2012 (GDUFA) enables FDA to assess
user fees to fund critical and measurable
improvements to FDA’s generic drugs
program. This guidance is intended to
assist applicants preparing to submit to
FDA prior approval supplements (PASs)
and amendments to PASs for
abbreviated new drug applications
(ANDAs). It describes FDA’s
performance metric goals for PASs and
clarifies how FDA will handle a PAS
SUMMARY:
E:\FR\FM\17OCN1.SGM
17OCN1
Agencies
[Federal Register Volume 81, Number 200 (Monday, October 17, 2016)]
[Notices]
[Page 71511]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2016-24947]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA-2014-N-0229]
Issuance of Priority Review Voucher; Rare Pediatric Disease
Product
AGENCY: Food and Drug Administration, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The Food and Drug Administration (FDA) is announcing the
issuance of a priority review voucher to the sponsor of a rare
pediatric disease product application. The Federal Food, Drug, and
Cosmetic Act (the FD&C Act), as amended by the Food and Drug
Administration Safety and Innovation Act (FDASIA), authorizes FDA to
award priority review vouchers to sponsors of rare pediatric disease
product applications that meet certain criteria. FDA has determined
that EXONDYS 51 (eteplirsen), manufactured by Sarepta Therapeutics,
meets the criteria for a priority review voucher.
FOR FURTHER INFORMATION CONTACT: Larry Bauer, Rare Diseases Program,
Center for Drug Evaluation and Research, Food and Drug Administration,
10903 New Hampshire Ave., Silver Spring, MD 20993-0002, 301-796-4842,
FAX: 301-796-9858, email: larry.bauer@fda.hhs.gov.
SUPPLEMENTARY INFORMATION: FDA is announcing the issuance of a priority
review voucher to the sponsor of a rare pediatric disease product
application. Under section 529 of the FD&C Act (21 U.S.C. 360ff), which
was added by FDASIA, FDA will award priority review vouchers to
sponsors of rare pediatric disease product applications that meet
certain criteria. FDA has determined that EXONDYS 51 (eteplirsen),
manufactured by Sarepta Therapeutics, meets the criteria for a priority
review voucher. EXONDYS 51 (eteplirsen) is indicated for the treatment
of Duchenne muscular dystrophy (DMD) in patients who have a confirmed
mutation of the DMD gene that is amenable to exon 51 skipping.
For further information about the Rare Pediatric Disease Priority
Review Voucher Program and for a link to the full text of section 529
of the FD&C Act, go to https://www.fda.gov/ForIndustry/DevelopingProductsforRareDiseasesConditions/RarePediatricDiseasePriorityVoucherProgram/default.htm. For further
information about EXONDYS 51 (eteplirsen) go to the ``Drugs@FDA'' Web
site at https://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm.
Dated: October 6, 2016.
Leslie Kux,
Associate Commissioner for Policy.
[FR Doc. 2016-24947 Filed 10-14-16; 8:45 am]
BILLING CODE 4164-01-P